Clorox Co. (CLX) Misses Q3 EPS, Rev Views; Guides FY 2015 EPS Below the Street

Clorox Co. (NYSE: CLX) reported Q3 EPS of $1.05, or $1.18 excluding the negative impact of 13 cents diluted EPS related to an effective currency devaluation in Venezuela, versus teh analyst estimate of $1.08. Revenue for the quarter came in at $1.39 billion versus the consensus estimate of $1.43 billion.

Sees FY 2014 sales down slightly (2% increase, currency neutral) and $4.25-$4.35 diluted EPS range ($4.40 to $4.50, excluding Venezuela devaluation). The consensus is $4.45.

Sees FY 2015 sales about flat (1-3% increase, currency neutral) and $4.35-$4.50 diluted EPS range. The consensus is $4.75.

"We're pleased to have delivered 5 percent diluted EPS growth in the third quarter, notwithstanding the Venezuela devaluation," said Chairman and CEO Don Knauss. "Looking ahead to the fourth quarter and fiscal year 2015, our top priority is to invest significantly in demand-building programs that will help grow our categories and market shares. Importantly, in fiscal year 2015, we anticipate delivering earnings per share growth, even with significant brand investment and anticipated continuing foreign currency declines."

For earnings history and earnings-related data on Clorox Co. (CLX) click here.

You May Also Be Interested In

• Citrini flags overheating concerns as leverage, chip rally weigh on KOSPI
• Morgan Stanley lifts server market TAM to $809B, boosts targets on compute stocks
• Wealthfront launches custodial account with tax-gain harvesting